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Background: The present study focused on the prognostic roles of PIK3CA and PIK3R1 genes and additional PI3K
pathway-associated genes in breast cancer.
Methods: The mutational and mRNA expression status of PIK3CA, PIK3R1 and AKT1, and expression status of other
genes involved in the PI3K pathway (EGFR, PDK1, PTEN, AKT2, AKT3, GOLPH3, WEE1, P70S6K) were assessed in a series
of 458 breast cancer samples.
Results: PIK3CA mutations were identified in 151 samples (33.0%) in exons 1, 2, 9 and 20. PIK3R1 mutations were
found in 10 samples (2.2%) and underexpression in 283 samples (61.8%). AKT1 mutations were found in 15 samples
(3.3%) and overexpression in 116 samples (25.3%). PIK3R1 underexpression tended to mutual exclusivity with
PIK3CA mutations (p = 0.00097). PIK3CA mutations were associated with better metastasis-free survival and PIK3R1
underexpression was associated with poorer metastasis-free survival (p = 0.014 and p = 0.00028, respectively). By
combining PIK3CA mutation and PIK3R1 expression status, four prognostic groups were identified with significantly
different metastasis-free survival (p = 0.00046). On Cox multivariate regression analysis, the prognostic significance
of PIK3R1 underexpression was confirmed in the total population (p = 0.0013) and in breast cancer subgroups.
Conclusions: PIK3CA mutations and PIK3R1 underexpression show opposite effects on patient outcome and could
become useful prognostic and predictive factors in breast cancer.
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The phosphatidylinositol 3-kinase (PI3K) pathway has
been identified as an important player in cancer develop-
ment and progression. Following receptor tyrosine kin-
ase activation, PI3K kinase phosphorylates inositol lipids
to phosphatidylinositol-3,4,5-trisphosphate. The level of
phosphatidylinositol-3,4,5-trisphosphate is regulated by
phosphatase activity of PTEN. Signal transmission sub-
sequently leads to PDK1 followed by activation of AKT.
AKT then regulates activation of the pathway down-
stream effectors, including mTOR and subsequently
P70S6K as well as other targets such as GSK3, WEE1
or BAD. mTOR has been found to be positively* Correspondence: ivan.bieche@curie.net
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reproduction in any medium, provided the orregulated by GOLPH3. The PI3K pathway controls
important cellular processes such as protein synthesis,
cell growth and proliferation, angiogenesis, cell cycle
and survival [1-3].
PI3K pathway deregulation is frequent in tumor cells
and can be caused by multiple changes affecting differ-
ent levels of the signaling cascade. These changes in-
clude gene amplifications, mutations and expression
alterations. However, various patterns of PI3K pathway
changes have been identified in different cancer types. In
breast cancer, such events commonly affect receptor
tyrosine kinases, PTEN, PIK3CA and, to a lesser degree,
AKT1. PIK3CA as well as AKT1 mutations have been
described as early events in the breast cancer develop-
ment process [3-6].
PI3K is a heterodimer and consists of a p110α catalytic
subunit encoded by the PIK3CA gene and a p85 regula-
tory subunit alpha encoded by the PIK3R1 gene [7-11].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hot spot mutations located in exons 9 and 20, corre-
sponding to the helical (E542K and E545K) and kinase
(H1047R) domains, respectively. PIK3CA mutations are
among the most common mutations, as they are ob-
served in 10 to 40% of breast cancer cases, depending
on the breast cancer subtype [3,4,8,12]. PIK3CA carrying
a hotspot mutation exerts an oncogenic activity: it can
transform primary fibroblasts in culture, induce anchorage-
independent growth, and cause tumors in animals [13,14].
Apart from exons 9 and 20, PIK3CA has been recently
shown to be also mutated frequently in other exons, as
demonstrated by Cheung et al. in the case of endometrial
cancer [15]. On the contrary, the PIK3R1 gene appears
to play a tumor suppressor role because PI3K subunit
p85α (p85α) regulates and stabilizes p110α [7,16].
PIK3R1 has also been recently found to be mutated
in breast cancer, but with a considerably lower frequency
(about 3%) than PIK3CA [17]. The impact of its suppres-
sor activity needs to be further described in breast cancer.
It is noteworthy that other PI3K subunit encoding genes
(PIK3CB, PIK3CD, PIK3CG, PIK3R2, PIK3R3) are altered
with much lower frequency than PIK3CA and PIK3R1
[17]. Loss of PTEN expression, observed in about 20-30%
of cases, is known to be one of the most common tumor
changes leading to PI3K pathway activation in breast
cancer [4].
Discordant reports have been published concerning
the prognostic role of PIK3CA mutations [4,18,19].
These mutations appear to be preferentially associated
with more favorable clinicopathologic characteristics and
more favorable outcome in breast cancer patients [3].
PIK3R1 underexpression might possibly lead to PI3K
pathway activation and confer tumor development and
progression in humans in a similar way to that observed
in a mouse model of hepatocellular cancer [16].
In the present study, we explored the two genes encod-
ing PI3K subunits and their role in PI3K pathway deregu-
lation and patient survival. PIK3CA, PIK3R1 and AKT1
mRNA expression levels and mutations were studied. We
also assessed mRNA expression levels of other genes in-
volved in the PI3K pathway, namely EGFR, PDK1, PTEN,
AKT1, AKT2, AKT3, GOLPH3, P70S6K, and WEE1 to
elucidate the pathway deregulations associated with chan-
ged PIK3CA and PIK3R1 states. PTEN and p85 protein
expression were also assessed by immunohistochemistry.
Methods
Patients and samples
We analyzed 458 samples of unilateral invasive primary
breast tumors excised from women at the Institut Curie/
Hôpital René Huguenin (Saint-Cloud, France) from 1978
to 2008 (Additional file 1: Table S1) where majority of
the patients were diagnosed and treated between years1990 and 2000 (67%). All patients admitted to our insti-
tution before 2007 were informed that their tumor sam-
ples might be used for scientific purposes and they were
given the opportunity to refuse the use of their samples.
Since 2007, patients admitted to our institution also give
their approval by signing an informed consent form.
This study was approved by the local ethics committee
(René Huguenin Hospital Breast Group). Patients (mean
age: 61.7 years, range: 31–91) met the following criteria:
primary unilateral non-metastatic breast carcinoma,
with full clinical, histological and biological data; no
radiotherapy or chemotherapy before surgery; and full
follow-up at Institut Curie/Hôpital René Huguenin.
Median follow-up was 8.6 years (range: 4.3 months to
28.9 years). One hundred and seventy patients devel-
oped metastases.
Samples were examined histologically and were con-
sidered suitable for this study when the proportion of
tumor cells exceeded 70% with sufficient cellularity, as
demonstrated by evaluation of tumor samples stained by
hematoxylin and eosin. Immediately following surgery,
tumor samples were placed in liquid nitrogen until RNA
extraction and also stored as formalin-fixed paraffin-
embedded tumor tissue sample blocks for immunohisto-
chemistry analysis.
Treatment consisted of modified radical mastectomy
in 283 cases (63.9%) and breast-conserving surgery plus
locoregional radiotherapy in 160 cases (36.1%). None of
the ERBB2-positive patients was treated by anti-ERBB2
therapy. Clinical examinations were performed every 3
or 6 months for the first 5 years according to the prog-
nostic risk of the patients, then yearly. Mammograms
were done annually. Adjuvant therapy was administered
to 358 patients, consisting of chemotherapy alone in 90
cases, hormone therapy alone in 175 cases and both
treatments in 93 cases. The histological type and num-
ber of positive axillary nodes were established at the
time of surgery. The malignancy of infiltrating carcin-
omas was scored with Bloom and Richardson’s histo-
prognostic system.
Estrogen receptor (ER) and progesterone receptor (PR)
status was determined at the protein level by using bio-
chemical methods (dextran-coated charcoal method or
enzyme immunoassay) until 1999 and then by immuno-
histochemistry. The cutoff for estrogen and progesterone
receptor positivity was set at 15 fm/mg (dextran-coated
charcoal or enzyme immunoassay) and 10% immuno-
stained cells (immunohistochemistry). A tumor was con-
sidered ERBB2-positive by IHC when it scored 3+ with
uniform intense membrane staining > 30% of invasive
tumor cells. Tumors scoring 2+ were considered to be
equivocal for ERBB2 protein expression and were tested
by FISH for ERBB2 gene amplification. In all cases, the
ERα, PR and ERBB2 status was also confirmed by real-
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vious studies comparing results of the these methods
[20-23]. Based on HR (ERα and PR) and ERBB2 status,
the 458 patients were subdivided into 4 subgroups as fol-
lows: HR- (ER- and PR-)/ERBB2- (n = 69), HR- (ER- and
PR-)/ERBB2+ (n = 45), HR + (ER + or/and PR+)/ERBB2-
(n = 290) and HR + (ER + or/and PR+)/ERBB2+ (n = 54).
RNA extraction
Total RNA was extracted from breast tumor samples by
using the acid-phenol guanidium method. The quantity
of RNA was assessed by using an ND-1000 NanoDrop
Spectrophotometer with its corresponding software
(Thermo Fisher Scientific Inc., Wilmington, DE). RNA
quality was determined by electrophoresis through agar-
ose gel and staining with ethidium bromide. The 18S
and 28S RNA bands were visualized under ultraviolet
light. DNA contamination was quantified by using a pri-
mer pair located in an intron of the gene encoding albu-
min (gene ALB). Only samples with a cycle threshold
(Ct) using these ALB intron primers greater than 35
were used for subsequent analysis.
Mutation screening
PIK3CA mutations (exons 1, 2, 9, 20), PIK3R1 (exons
11–15) and AKT1 (exon 4) were detected by sequencing
of cDNA fragments obtained by RT-PCR amplification.
Exons to be screened in the three genes were chosen
following mutational frequency described at COSMIC:
Catalogue Of Somatic Mutations In Cancer (cancer.sanger.
ac.uk/). Screening by high-resolution melting curve ana-
lysis was performed on PIK3CA exons 1 and 2, AKT1
exon 4 and PIK3R1 exons 11 to 15 on a LightCycler
480 (Roche Diagnostics, Penzberg, Germany) using
LCGreen Plus + Melting Dye fluorescence (Biotech,
Idaho Technology Inc., Salt Lake City, UT). Details of the
primers and PCR conditions are available on request. The
amplified products were sequenced with the BigDye
Terminator kit on an ABI Prism 3130 automatic DNA se-
quencer (Applied Biosystems, Courtaboeuf, France) with
detection sensitivity of 5% mutated cells, and the se-
quences were compared with the corresponding cDNA
reference sequences (PIK3CA NM_006218, PIK3R1
NM_181523, AKT1 NM_005163). All detected mutations
were confirmed in the second independent run of sample
testing.
Real-time quantitative RT-PCR
RT-PCR was applied to the selected genes and to TBP
(NM_003194) as endogenous mRNA control. Primers
are listed in Additional file 2: Table S2. PCR conditions
are available on request. The RT-PCR protocol using
the SYBR Green Master Mix kit on the ABI Prism
7900 Sequence Detection System (Perkin-Elmer AppliedBiosystems, Foster City, CA) is described in detail else-
where [20]. The relative mRNA expression level of each
gene, expressed as the N-fold difference in target gene ex-
pression relative to the TBP gene, and termed “Ntarget”,
was calculated as Ntarget = 2ΔCtsample. The value of the
cycle threshold (ΔCt) of a given sample was determined
by subtracting the average Ct value of the target gene from
the average Ct value of the TBP gene. The Ntarget values
of the samples were subsequently normalized so that the
median Ntarget value of normal breast samples was 1.
Cut-offs for normalized values ≤ 0.5 and ≥ 2.0 were used
to determine gene underexpression and overexpression,
respectively.
Immunohistochemistry
PTEN and p85 protein expression levels were assessed
by immunohistochemistry staining on tumor sections
from formalin-fixed paraffin-embedded blocks. Indirect
immunoperoxidase staining was performed using mouse
monoclonal antibody directed against human PTEN pro-
tein (Dako, Glostrup, Denmark) and rabbit polyclonal
antibody directed against human p85 protein (Signalway
Antibody, Baltimore, Maryland). The localization and in-
tensity of staining were assessed by two independent pa-
thologists blinded to real-time RT–PCR results.
Both antibodies were used at a 1/50 dilution. The im-
munohistochemical procedure was performed as de-
scribed below, using a water bath antigen-retrieval
technique in each case. Sections were mounted on pre-
coated slides (Dako, Glostrup, Denmark) and allowed to
dry at 50°C overnight. Sections were then dewaxed in
xylene and hydrated by graded dilutions of ethanol.
Endogenous activity was blocked with 1% hydrogen per-
oxide for 15 min. Sections were then immersed in a
heat-resistant plastic box containing 10 ml of pH 9.0 cit-
rate buffer and processed in the water bath for 40 min.
Sections were then allowed to cool to room temperature
for 20 min before rinsing in H2O. The blocking reagent
was poured off and the primary antibodies were left for
25 min. A standard avidin–biotin–peroxidase complex
(LSAB) method was used to reveal the antibody–antigen
reaction (Dako, Glostrup, Denmark). Autostainer link 48
was used for the staining process (Dako, Glostrup,
Denmark).
Normal ductal epithelial cells showed a positive cyto-
plasmic immunostaining, whereas PTEN expression in
tumor cells varied with cytoplasmic and/or nuclear stain-
ing. A semi-quantitative intensity score was performed
(score 0: negative staining, score 1: weak cytoplasmic
staining, score 2: moderate cytoplasmic staining, score 3:
strong and diffuse cytoplasmic staining). Positive immu-
nohistochemical reactions were defined as a brown cyto-
plasmic staining for p85. A semi-quantitative intensity
scale ranging from 0 for no staining to 3+ for the most
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cells to adjacent breast cells belonging to normal ter-
minal ductulo-lobular units. p85 underexpression was
defined by an IHC score 0, p85 normal expression by
an IHC score 1, and p85 overexpression by an IHC
score 2+ and 3+.
Statistical analysis
Relationships between tumor changes (expressed as mu-
tational or expression status) and clinical, histological
and biological parameters were estimated with the Chi2
test. A level of significance was set at 5%. Metastasis-free
survival (MFS) was determined as the interval between
diagnosis and detection of the first metastasis. Survival
distributions were estimated by the Kaplan-Meier
method [24], and the significance of differences between
survival rates was ascertained with the log-rank test [25].
Cox’s proportional hazards regression model [26] was
used to assess prognostic significance in multivariate
analysis.
Results
PIK3CA, PIK3R1 and AKT1 mutational analysis
The present study extends our previously published data
describing the positive effect of PIK3CA exon 9 and 20
mutations on breast cancer patient survival [12]. In the
present study, PIK3CA mutations were additionally
assessed in exons 1 and 2. PIK3CA mutations were iden-
tified in 151 (33.0%) of the 458 samples, in line with pre-
vious studies in which PIK3CA mutations were found in
10 to 40% of breast cancer cases [3,4,8]. Sixty-three tu-
mors showed PIK3CA mutations located in exon 9, 85
tumors showed mutations in exon 20, and one tumor
showed mutations in both exon 9 and exon 20. Five mu-
tations were found in exon 1, including two cases with 3
nucleotide deletions (c.305_307del and c.328_330del).
Three other mutated tumors showed point mutations
(R115L in one case and R108H in two cases). Two tu-
mors showed mutations in exon 2 (both G118D). Point
mutations in exons 1 and 2 were always found in cases
mutated in either exon 9 or exon 20, but the two tumors
with deletions did not present any additional PIK3CA
mutations in other exons. Breast cancer subgroup ana-
lysis demonstrated PIK3CA mutations with the lowest
frequency (10/69; 14.5%) in HR-/ERBB2- tumors and the
highest frequency (118/290; 40.7%) in HR+/ERBB2- tu-
mors, while an intermediate frequency of PIK3CA muta-
tions was observed in HR-/ERBB2+ and HR+/ERBB2+
tumors (9/45; 20.0% and 14/54; 25.9%, respectively).
PIK3R1 mutations were screened in exons 11–15 and
were present in 10 (2.2%) of the 454 available samples
(Additional file 3: Table S3). Seven cases of deletions of
3-nucleotide multiples were observed in exons 11 and
13 (in the area between nucleotides 1345–1368 and1701–1743, respectively), 2 cases of duplications of 3-
nucleotide multiples were observed in exon 13 (in the
area between nucleotides 1650–1723) and 1 case of point
mutations were observed in exon 15 (c.1925G > T). It is
noteworthy that we found also c.1590G > A giving the
AAG –> AAA (Lys) nucleotide substitution located in
exon 13 that is probably a polymorphism with no amino
acid change. PIK3R1 mutations were found in only 1 of
the 151 PIK3CA-mutated cases and in 10 of the 297
PIK3CA wild-type cases. The low frequency of PIK3R1
mutations did not allow any further statistical analysis
concerning a possible association between PIK3R1 muta-
tions and clinical, histological and biological parameters.
AKT1 mutation (E17K) was found in 15 (3.3%) of the
457 available samples. AKT1 mutations were found in
only 1 of the 161 PIK3CA/PIK3R1-mutated cases and
14 of the 297 PIK3CA/PIK3R1 wild-type cases and
tended therefore to mutual exclusivity with PI3K mu-
tations (p = 0.019).
Altogether, we observed PIK3CA and/or PIK3R1 and/
or AKT1 mutations in 174/454 (38.3%) breast cancer
tumors. Breast cancer subgroup analysis demonstrated
mutation of at least one of the three genes with the
highest frequency in HR+/ERBB2- tumors (133/289;
46.0%). The other 3 breast cancer subtypes showed a
lower frequency of these mutations: HR+/ERBB2+ in
15/54 (27.8%), HR-/ERBB2+ in 10/43 (23.3%) and
HR-/ERBB2- in 16/68 (23.5%).
mRNA expression
The PIK3CA, PIK3R1 and AKT1 mRNA expression
levels were assessed in the whole series of 458 samples.
PIK3R1 underexpression was found in 283 (61.8%) cases,
indicating a relevant tumor alteration occurring in the
majority of tumor samples (Table 1). Moreover, when
assessing breast cancer subgroups, PIK3R1 was predom-
inantly underexpressed in HR-/ERBB2- and HR-/ERBB2+
tumors (p < 0.0000001) (Table 2), while PIK3CA was
deregulated in only a minority of tumor samples: over-
expressed in 18 (3.9%) and underexpressed in 40
(8.7%) cases (Table 1). PIK3CA expression did not
vary significantly between the four breast cancer sub-
groups based on hormone and ERBB2 receptor status
(Table 2). Expression levels of PIK3CA, the oncogene
bearing the highest number of mutations in breast
cancer, were therefore mostly stable in breast cancer
subgroups indicating that mutations constituted the
main tumor change affecting PIK3CA. These results
show that changes of expression of PIK3R1 but not
PIK3CA play a role in breast cancer, specifically in
hormone receptor-negative cases.
AKT1 overexpression was present in 116 (25.3%) of
the 458 available samples, mostly in HR-/ERBB2+ and
HR+/ERBB2+ tumors (p = 0.00019) (Table 2). Seven of
Table 1 Gene mRNA levels in 458 breast tumors
Genes Median Ct of
normal breast
tissue (n = 10)
Normal breast
tissue (n = 10)
















EGFR 30.2 (29.3-31.5)a 1.0 (0.7 -1.3)b 0.2 (0.0-112.9)b 84.9%c 13.3%c 1.8%c 0.7%c
PIK3CA 29.7 (28.4-31.0) 1.0 (0.7-1.3) 0.9 (0.2-33.4) 8.7% 87.4% 3.9% 0.7%
PIK3R1 26.8 (25.8-28.1) 1.0 (0.7-1.5) 0.4 (0.0-5.2) 61.8% 36.0% 2.2% 0.2%
PDK1 31.8 (29.7-33.5) 1.0 (0.5-1.9) 1.0 (0.0-14.7) 13.3% 69.0% 17.7% 2.2%
PTEN 26.4 (25.3-31.3) 1.1 (0.7-2.0) 0.8 (0.1-9.0) 17.0% 81.0% 2.0% 0.4%
AKT1 28.7 (27.5-30.1) 1.0 (0.7-1.5) 1.5 (0.0-11.1) 1.3% 73.4% 25.3% 2.8%
AKT2 26.7 (25.4-29.7) 1.0 (0.7-2.0) 1.7 (0.5-12.2)d 0.0% 64.0% 36.0% 3.3%
AKT3 26.0 (23.8-28.4) 1.0 (0.6-1.9) 0.4 (0.0-7.5)d 67.1% 31.1% 1.8% 0.2%
GOLPH3 27.9 (26.4-29.0) 1.0 (0.8-1.6) 1.4 (0.3-6.7) 0.7% 79.9% 19.4% 0.9%
P70S6K 31.2 (29.9-32.7) 1.0 (0.7-1.8) 1.2 (0.0-19.6) 2.2% 79.7% 18.1% 3.7%
WEE1 28.4 (26.1-29.8) 1.0 (0.5-1.6) 0.8 (0.2-6.9) 18.3% 77.3% 4.4% 0.2%
aMedian (range) of gene Ct values.
bMedian (range) of gene mRNA levels; the mRNA values of the samples were normalized so that the median of the 10 normal breast tissue mRNA values was 1.
cPercentages of underexpressing, normal and overexpressing tumors using cut-offs of Ntarget ≤0.5 and Ntarget ≥2.
dData available in 456 samples.
The bold numbers stress important finding or overall characterisation of a group or p-value.
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AKT1 expression. However, AKT1 mutation and expres-
sion status as well as expression changes in other genes
of the PI3K/AKT pathway did not show any statistically
significant association (data not shown) possibly because
of the small number of AKT1 mutated cases.
mRNA expression levels of other genes involved in the
PI3K/AKT pathway were also evaluated., i.e. EGFR,
PDK1, PTEN, AKT2 and 3, GOLPH3, P70S6K, and
WEE1 (Table 1). Markedly high expression that might be
caused by gene amplification was observed only in low
frequency (<4%) of tumors as shows the last colon in the
Table 1. PTEN underexpression was significantly mutu-
ally exclusive with PIK3CA, PIK3R1 and AKT1 muta-
tions (p = 0.00016), as it was observed in only one AKT1
mutated tumor and 14 PIK3CA mutated tumors. Ex-
pression levels were also compared in the four breast
cancer subgroups as shown in Table 2. Interestingly,
gene expressions were deregulated in different ways in
the 4 subgroups. EGFR underexpression was demon-
strated in all subgroups, as previously published [27].
P70S6K and AKT1 was predominantly overexpressed
in ERBB2+ tumors (p < 0.0000001 and 0.00019, respect-
ively). This increased expression of these two genes might
be linked to the PI3K/AKT pathway activated by ERBB2
overexpression. On the other hand, expression changes
in HR-/ERBB2- tumors might indicate downstream
activation of the pathway occurring despite the nega-
tivity of ERBB2. The 4 molecular subgroups of breast
cancer therefore appeared to undergo distinct changes
at the levels of mRNA expression of the genes in-
volved in the PI3K/AKT pathway. These data wouldbenefit from confirmation at protein level (both quan-
tity and activity).
The next step of analysis focused on PI3K constitu-
ents, specifically PIK3R1 expression and PIK3CA muta-
tions in relation to expression levels of the other genes
evaluated. Tumors characterized by PIK3R1 underexpres-
sion were associated with deregulation of other genes
involved in the PI3K/AKT pathway (Table 3). PIK3R1
underexpression was negatively associated with PIK3CA
mutations (p = 0.00097) and these two parameters were
therefore predominantly mutually exclusive. In contrast to
PIK3R1, deregulation of the expression of genes involved
in the PI3K/AKT pathway was almost exclusively associ-
ated with PIK3CA wild-type tumors (Table 4).
Immunohistochemistry
Alteration of p85 (encoded by PIK3R1) and PTEN ex-
pression was also verified at the protein level by im-
munohistochemistry in randomly selected samples
with low and high mRNA expression. In both cases, sam-
ples showing decreased mRNA expression (5 PIK3R1
underexpressed- and 5 PTEN underexpressed-tumors)
also presented low immunohistochemical staining inten-
sity. Similarly, samples showing normal mRNA expression
(7 PIK3R1 expressing and 8 PTEN expressing tumors)
presented strong immunohistochemical staining intensity.
The only exceptions were two samples stained for PTEN
(one showing low mRNA expression and more intense
immunohistochemistry staining, the other showing oppos-
ite features). A good match (23/25 samples tested) was
therefore obtained between mRNA and protein expression
status for both PIK3R1 and PTEN (Figure 1). These results
Table 2 Genes mRNA levels in the 4 breast tumor subtypes
All tumors Tumor subtypes
HR-ERBB2- HR-ERBB2+ HR + ERBB2- HR + ERBB2+ P-valuea
n = 458 n = 69 n = 45 n = 290 n = 54
PIK3CA values: median [range] 0.9 (0.2-33.4) 0.9 (0.3-33.4) 0.7 (0.3-1.7) 0.9 (0.2-5.9) 1.0 (0.4-5.6) NS
Underexpressed tumors (%) 40 (8.7) 6 (8.7) 5 (11.1) 25 (8.6) 4 (7.4)
Non-underexpressed tumors (%) 418 (91.3) 63 (91.3) 40 (88.9) 265 (91.4) 50 (92.6)
PIK3R1 values: median [range] 0.4 (0.0-5.2) 0.2 (0.0-2.2) 0.3 (0.1-1.5) 0.5 (0.1-4.4) 0.4 (0.1-5.2) <0.0000001
Underexpressed tumors (%) 283 (61.8) 61 (88.4) 40 (88.9) 150 (51.7) 32 (59.3)
Non-underexpressed tumors (%) 175 (38.2) 8 (11.6) 5 (11.1) 140 (48.3) 22 (40.7)
PDK1 values: median [range] 1.0 (0.0-14.7) 2.4 (0.5-14.7) 1.7 (0.4-6.2) 0.9 (0.0-3.3) 0.9 (0.1-2.4) <0.0000001
Underexpressed tumors (%) 61 (13.3) 0 1 (2.2) 51 (7.9) 9 (16.6)
Normally expressed tumors (%) 316 (69.0) 25 (36.2) 27 (60.0) 221 (90.0) 43 (79.6)
Overexpressed tumors (%) 81 (17.7) 44 (63.8) 17 (37.8) 18 (2.1) 2 (3.7)
PTEN values: median [range] 0.8 (0.1-9.0) 0.6 (0.1-1.5) 0.8 (0.3-1.9) 0.8 (0.1-9.0) 0.9 (0.4-3.3) 0.0000066
Underexpressed tumors (%) 78 (17.0) 27 (39.1) 6 (13.3) 39 (13.4) 6 (11.1)
Non-underexpressed tumors (%) 380 (83.0) 42 (60.9) 39 (86.7) 251 (86.6) 48 (88.9)
AKT1 values: median [range] 1.5 (0.0-11.1) 1.1 (0.0-11.1) 2.0 (0.6-10.0) 1.4 (0.4-6.1) 1.8 (0.6-9.9) 0.00019
Non-overexpressed tumors (%) 342 (74.7) 55 (79.7) 24 (53.3) 230 (79.3) 33 (61.1)
Overexpressed tumors (%) 116 (25.3) 14 (20.3) 21 (46.7) 60 (20.7) 21 (38.9)
AKT2 values: median [range]b 1.7 (0.5-12.2) 1.7 (0.7-12.2) 1.4 (0.8-8.7) 1.8 (0.5-10.6) 1.8 (0.5-7.0) 0.0097
Non-overexpressed tumors (%) 293 (64.3) 46 (67.6) 38 (84.4) 180 (62.3) 29 (53.7)
Overexpressed tumors (%) 163 (35.7) 22 (32.4) 7 (15.6) 109 (37.7) 25 (46.3)
AKT3 values: median [range]b 0.4 (0.0-7.5) 0.5 (0.0-2.2) 0.3 (0.1-0.9) 0.4 (0.0-7.5) 0.4 (0.1-2.3) NS
Underexpressed tumors (%) 306 (67.1) 38 (55.9) 32 (71.1) 198 (68.5) 38 (70.4)
Non-underexpressed tumors (%) 150 (32.9) 30 (44.1) 13 (28.9) 91 (31.5) 16 (29.6)
GOLPH3 values: median [range] 1.4 (0.3-6.7) 1.2 (0.6-3.3) 1.4 (0.7-5.0) 1.3 (0.3-6.7) 1.7 (0.8-5.4) NS
Non-overexpressed tumors (%) 369 (80.6) 54 (78.3) 36 (80.0) 241 (83.1) 38 (70.4)
Overexpressed tumors (%) 89 (19.4) 15 (21.7) 9 (20.0) 49 (16.9) 16 (29.6)
P70S6K values: median [range] 1.2 (0.0-19.6) 1.0 (0.0-5.4) 1.9 (0.6-9.9) 1.2 (0.3-8.0) 1.4 (0.4-19.6) <0.0000001
Non-overexpressed tumors (%) 375 (81.9) 64 (92.8) 24 (53.3) 250 (86.2) 37 (68.5)
Overexpressed tumors (%) 83 (18.1) 5 (7.2) 21 (46.7) 40 (13.8) 17 (31.5)
WEE1 values: median [range] 0.8 (0.2-6.9) 0.7 (0.2-6.9) 0.9 (0.3-2.8) 0.8 (0.2-3.9) 0.8 (0.3-4.1) 0.0014
Underexpressed tumors (%) 84 (18.3) 24 (34.8) 6 (13.3) 43 (14.8) 11 (20.4)
Non-underexpressed tumors (%) 374 (81.7) 45 (65.2) 39 (86.7) 247 (85.2) 43 (79.6)
aChi2 test of independency in contingency tables (tumor subtype vs. gene expression). NS: not significant.
bData available in 456 samples.
The bold numbers stress important finding or overall characterisation of a group or p-value.
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is mainly transcriptional.
Survival analysis
Survival curves were compared to assess the possible
impact of these expression changes and mutations on
patient outcome. Additional file 4: Table S4 summarizes
survival analysis performed on the overall patient series.
Patients presenting any of the mutations assessed in this
study (PIK3CA, PIK3R1 or AKT1) had a significantlybetter MFS (p = 0.024). Among the 11 genes studied,
only PIK3CA mutations and PIK3R1 underexpression, as
separate markers, were associated with MFS and had
opposite effects on patient survival: PIK3CA mutation
was associated with better MFS and PIK3R1 underex-
pression was associated with poorer MFS (p = 0.016
and p = 0.00028, respectively). PIK3R1 underexpres-
sion was associated with histological grade 3 status
and an increased rate of positive axillary lymph nodes
(p < 0.0000001 and p = 0.013, respectively). HR- and
Table 3 Comparison of PIK3R1 expression status and alterations of other genes of interest
Number of patients (%)
Total population (%) PIK3R1 underexpression PIK3R1 non-underexpression P-valuea
Total 458 (100.0) 283 (61.8) 175 (38.2)
EGFR values: median [range] 0.2 (0.0-112.9) 0.1 (0.0-7.3) 0.2 (0.0-112.9)
Underexpressed tumors (%) 389 (84.9) 250 (88.3) 139 (79.4) 0.0096
Non-underexpressed tumors (%) 69 (15.1) 33 (11.7) 36 (20.6)
PDK1 values: median [range] 1.0 (0.0-14.7) 1.2 (0.1-14.7) 0.9 (0.0-6.2)
Underexpressed tumors (%) 61 (13.3) 26 (9.2) 35 (20.0) 0.000004
Normally expressed tumors (%) 316 (69.0) 189 (66.8) 127 (72.6)
Overexpressed tumors (%) 81 (17.7) 68 (24.0) 13 (7.4)
AKT1 values: median [range] 1.5 (0.0-11.1) 1.4 (0.4-10.0) 1.6 (0.0-11.1)
Non-overexpressed tumors (%) 342 (74.7) 216 (76.3) 126 (72.0) NS
Overexpressed tumors (%) 116 (25.3) 67 (23.7) 49 (28.0)
AKT2 values: median [range]b 1.0 (0.7-2.3) 1.6 (0.5-10.6) 1.8 (0.5-12.2)
Non-overexpressed tumors (%) 293 (64.3) 189 (67.0) 104 (59.8) NS
Overexpressed tumors (%) 163 (35.7) 93 (33.0) 70 (40.2)
AKT3 values: median [range]b 1.0 (0.4-1.9) 0.3 (0.0-2.4) 0.5 (0.1-7.5)
Underexpressed tumors (%) 306 (67.1) 215 (76.2) 91 (52.3) 0.00000013
Non-underexpressed tumors (%) 150 (32.9) 67 (23.8) 83 (47.7)
GOLPH3 values: median [range] 1.4 (0.3-6.7) 1.3 (0.3-5.2) 1.7 (0.7-6.7)
Non-overexpressed tumors (%) 369 (80.6) 242 (85.5) 127 (72.6) 0.00067
Overexpressed tumors (%) 89 (19.4) 41 (14.5) 48 (27.4)
P70S6K values: median [range] 1.2 (0.0-19.6) 1.2 (0.4-19.6) 1.2 (0.0-8.9)
Non-overexpressed tumors (%) 375 (81.9) 226 (79.9) 149 (85.1) NS
Overexpressed tumors (%) 83 (18.1) 57 (20.1) 26 (14.9)
WEE1 values: median [range] 0.8 (0.2-6.9) 0.7 (0.2-4.1) 0.9 (0.2-6.9)
Underexpressed tumors (%) 84 (18.3) 68 (24.0) 16 (9.1) 0.000063
Non-underexpressed tumors (%) 374 (81.7) 215 (76.0) 159 (90.9)
PTEN values: median [range] 0.8 (0.1-9.0) 0.7 (0.1-9.0) 1.0 (0.4-5.8)
Underexpressed tumors (%) 78 (17.0) 71 (25.1) 7 (4.0) < 0.0000001
Non-underexpressed tumors (%) 380 (83.0) 212 (74.9) 168 (96.0)
PIK3CA
Wild-type (%) 307 (67.0) 205 (72.4) 102 (58.3) 0.0017
Mutation (%) 151 (33.0) 78 (27.6) 73 (41.7)
PIK3R1c
Wild-type (%) 444 (97.8) 276 (98.6) 168 (96.6) NS
Mutation (%) 10 (2.2) 4 (1.4) 6 (3.4)
AKT1d
Wild-type (%) 442 (96.7) 272 (96.5) 170 (97.1) NS
Mutation (%) 15 (3.3) 10 (3.5) 5 (2.9)
aChi2 test. NS: not significant.
bData available in 456 samples.
cData available in 454 samples.
dData available in 457 samples.
The bold numbers stress important finding or overall characterisation of a group or p-value.
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Table 4 Comparison of PIK3CA mutational status and alterations in other genes of interest
Number of patients (%)
Total population (%) PIK3CA wild-type PIK3CA-mutated P-valuea
Total 458 (100.0) 307 (67.0) 151 (33.0)
EGFR values: median [range] 0.2 (0.0-112.9) 0.2 (0.0-112.9) 0.2 (0.0-7.3)
Underexpressed tumors (%) 389 (84.9) 256 (83.4) 133 (88.1) NS
Non-underexpressed tumors (%) 69 (15.1) 51 (16.6) 18 (11.9)
PIK3R1 values: median [range] 0.4 (0.0-5.2) 0.3 (0.0-4.4) 0.5 (0.1-5.2)
Underexpressed tumors (%) 283 (61.8) 205 (66.8) 78 (51.7) 0.0017
Non-underexpressed tumors (%) 175 (38.2) 102 (33.2) 73 (48.3)
PDK1 values: median [range] 1.0 (0.0-14.7) 1.1 (0.0-14.7) 0.8 (0.1-4.5)
Underexpressed tumors (%) 61 (13.3) 35 (11.4) 26 (17.2) 0.0011
Normally expressed tumors (%) 316 (69.0) 204 (66.5) 112 (74.2)
Overexpressed tumors (%) 81 (17.7) 68 (22.1) 13 (8.6)
PTEN values: median [range] 0.8 (0.1-9.0) 0.8 (0.1-5.8) 0.9 (0.1-9.0)
Underexpressed tumors (%) 78 (17.0) 64 (20.8) 14 (9.3) 0.0019
Non-underexpressed tumors (%) 380 (83.0) 243 (79.2) 137 (90.7)
AKT1 values: median [range] 1.5 (0.0-11.1) 1.5 (0.0-11.1) 1.5 (0.4-9.9)
Non-overexpressed tumors (%) 342 (74.7) 230 (74.9) 112 (74.2) NS
Overexpressed tumors (%) 116 (25.3) 77 (25.1) 39 (25.8)
AKT2 values: median [range]b 1.0 (0.7-2.3) 1.7 (0.5-12.2) 1.6 (0.5-10.6)
Non-overexpressed tumors (%) 293 (64.3) 190 (62.3) 103 (68.2) NS
Overexpressed tumors (%) 163 (35.7) 115 (37.7) 48 (31.8)
AKT3 values: median [range]b 1.0 (0.4-1.9) 0.4 (0.0-3.6) 0.4 (0.1-7.5)
Underexpressed tumors (%) 306 (67.1) 206 (67.5) 100 (66.2) NS
Non-underexpressed tumors (%) 150 (32.9) 99 (32.5) 51 (33.8)
GOLPH3 values: median [range] 1.4 (0.3-6.7) 1.4 (0.5-6.7) 1.3 (0.3-5.4)
Non-overexpressed tumors (%) 369 (80.6) 242 (78.8) 127 (84.1) NS
Overexpressed tumors (%) 89 (19.4) 65 (21.2) 24 (15.9)
P70S6K values: median [range] 1.2 (0.0-19.6) 1.2 (0.0-19.6) 1.1 (0.4-8.0)
Non-overexpressed tumors (%) 375 (81.9) 233 (75.9) 142 (94.0) 0.0000022
Overexpressed tumors (%) 83 (18.1) 74 (24.1) 9 (6.0)
WEE1 values: median [range] 0.8 (0.2-6.9) 0.8 (0.2-6.9) 0.7 (0.3-3.4)
Underexpressed tumors (%) 84 (18.3) 61 (19.9) 23 (15.2) NS
Non-underexpressed tumors (%) 374 (81.7) 246 (80.1) 128 (84.8)
PIK3R1c
Wild-type (%) 444 (97.8) 294 (97.0) 150 (99.3) NS
Mutation (%) 10 (2.2) 9 (3.0) 1 (0.7)
AKT1d
Wild-type (%) 442 (96.7) 292 (95.4) 150 (99.3) NS
Mutation (%) 15 (3.3) 14 (4.6) 1 (0.7)
aChi2 test. NS: not significant.
bData available in 456 samples.
cData available in 454 samples.
dData available in 457 samples.
The bold numbers stress important finding or overall characterisation of a group or p-value.
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Figure 1 Comparison of PIK3R1/p85 immunohistochemistry and mRNA expression results. A. Tumor sample with protein underexpression
(expression intensity +) and decreased mRNA expression (normalized mRNA expression value 0.05). B. Healthy tissue sample with normal protein
expression (expression intensity +++) and normal mRNA expression (normalized mRNA expression value 1.0).
Figure 2 Survival curves of four patient groups according to
PIK3R1 expression status and PIK3CA mutations.
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underexpression (p < 0.0000001 and p = 0.011, respect-
ively). These results show that PIK3R1 underexpression
predominantly occurred in tumors with poorer prognostic
markers (Additional file 5: Table S5). The combination of
these two molecular markers (PIK3CA mutations and
PIK3R1 underexpression) can be considered to provide
more accurate prediction of patient survival than when
they are considered separately. Combined analysis of
PIK3CA mutations and PIK3R1 expression status defined
four separate prognostic groups with significantly dif-
ferent survivals. Comparison of all four survival curves
showed statistical differences with p = 0.00046 (log-rank
test for 4-level factor, Figure 2). The least favorable sur-
vival was observed in the subgroup characterized by
PIK3CA wild-type and PIK3R1 underexpression and
the most favorable survival was observed in the sub-
group characterized by PIK3CA mutation without
PIK3R1 underexpression.
Multivariate analysis using a Cox proportional hazards
model (Table 5) assessed the predictive value for MFS of
the parameters found to be significant on univariate ana-
lysis (i.e., Scarff-Bloom-Richardson histological grade,
lymph node status, macroscopic tumor size, and ERα,
PR, and ERBB2 status, as well as PIK3CA mutation and
PIK3R1 expression status). This analysis confirmed a
trend towards an independent prognostic significance of
PIK3CA mutations only in ERBB2+ tumors (p = 0.051).Furthermore, the prognostic significance of PIK3R1 un-
derexpression persisted in the overall series (p = 0.0013)
and in breast cancer subgroups characterized by ERα +
(p = 0.0076), PR + (p = 0.043), ERBB2+ (p = 0.018) and
also ERBB2- (p = 0.024).
Table 5 Results of Cox multivariate analysis
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This study extends the previously obtained data con-
cerning the positive prognostic role of exon 9 and 20
PIK3CA mutations in breast cancer [12]. This study fo-
cused on PI3K signaling pathway, particularly the two
subunits of PI3K encoded by PIK3CA and PIK3R1 genes.
In addition to our previous study, PIK3CA mutations
were also assessed in exons 1 and 2 that have been re-
cently shown to be frequently mutated in endometrial
cancer [15]. PIK3CA mutations were detected in 33.0%
of cases (exons 1, 2, 9, 20) and PIK3R1 mutations were
detected in 2.2% of cases (exons 11, 12, 13, 15). The low
frequency of about 3% PIK3R1 mutations is in agree-
ment with published studies [17,28]. AKT1 mutations
(exon 4) were also assessed and detected in 3.3% of tu-
mors. This finding is also in agreement with previous
studies describing a moderate frequency of AKT1 muta-
tions in breast cancer and their association with positive
hormone receptor status [6]. PIK3CA, PIK3R1 and
AKT1 mutations were mutually exclusive and were ob-
served in a total of 175 breast cancer tumors. Interest-
ingly, PIK3R1 underexpression was observed in 61.8% of
breast cancer tumors. PIK3CA mutations were associ-
ated with better MFS and PIK3R1 underexpression was
associated with poorer MFS (p = 0.014 and p = 0.00028,
respectively). By combining PIK3CA mutation and
PIK3R1 expression states, we identified four prognostic
groups with significantly different MFS (p = 0.00046).
These new results suggest that PIK3CA mutations and
PIK3R1 underexpression are associated with opposite
prognostic impacts on breast cancer patient survival.
Multivariate analysis showed that PIK3R1 expression sta-
tus was an independent predictor of MFS in the total
population (p = 0.0013), whereas PIK3CA mutation sta-
tus only showed a trend in the ERBB2+ population (p =
0.051).
The frequency and associations of genomic and pro-
tein expression alterations in the PI3K pathway differ in
the various breast cancer subgroups. Additionally, some
alterations may co-exist, while others are mutually ex-
clusive. Mutually exclusive mutations have been previ-
ously reported for PIK3CA and AKT1 mutations [4]. We
and other teams have found PIK3CA mutations in 10 to
40% of breast cancer cases and AKT1 mutations in less
than 10% of cases [3-6,8,17]. Our data are in agreement
with the mutational frequencies described by other au-
thors. Our findings also support the data recently pub-
lished by Ellis et al., who described a low frequency of
exon 1 and 2 mutations in breast cancer. They also ob-
served missense mutations in these two exons occurring
in cases bearing additional PIK3CA mutations, whereas
one deletion in exon 1 was not accompanied by another
PIK3CA mutation [29]. The most frequent mutations
were E542K and E545K in exon 9 and H1047R in exon20 in keeping with most other studies [4,8,17,18]. We
also found that PIK3R1 mutations tended to mutual ex-
clusivity with PIK3CA and AKT1 mutations. PTEN loss
occurring in up to 30% of unselected breast tumor co-
horts is also predominantly mutually exclusive with
PIK3CA and AKT1 mutations [4,18]. PIK3R1 mutations
as well as combined mutations of the three genes stud-
ied were also found to be mutually exclusive with PTEN
underexpression (p = 0.00016). As PIK3CA and AKT1
are oncogenes activated by mutations and as PIK3R1
and PTEN are tumor suppressors mainly inactivated by
underexpression, respectively, all these alterations result
in PI3K pathway activation. The frequencies of PIK3CA,
PIK3R1 and AKT1 alteration differ according to breast
cancer subtypes. PIK3CA mutations have been previ-
ously described to occur most frequently in HR + breast
tumors [4,12]. The highest mutational frequency for all
of the genes assessed in this study (PIK3CA and/or
PIK3R1 and/or AKT1) was observed in HR+/ERBB2- tu-
mors (133/289; 46.0%), while mutations were observed
in up to 28% of cases in other breast cancer subtypes. In
terms of expression, PIK3R1 was underexpressed in
about 90% of HR- tumors, but only in about 55% of HR
+ breast cancers. Similarly, PTEN underexpression was
observed in 40% of triple-negative tumors versus 13% in
other breast cancer subtypes, suggesting different mech-
anisms underlining PI3K pathway deregulation in spe-
cific breast tumor subtypes.
The protein p85α encoded by the PIK3R1 gene has
been described to play an important role in PI3K path-
way signaling by stabilizing the other PI3K subunit –
p110α – encoded by PIK3CA gene [7,16,30]. Loss of the
p85α tumor suppressor effect leads to downstream PI3K
pathway activation. The impact of PIK3R1 deregulation
on pathway signaling could be caused by the impaired
ability of interaction of the two subunits and loss of the
inhibitory effect of p85α on p110α and PI3K activity
[7,28]. PIK3R1 has been reported to play a tumor sup-
pressor role in hepatocellular cancer and this tumor sup-
pressor effect is lost in the case of gene underexpression
[11,16]. Mostly point mutations and deletions have been
reported for PIK3R1, but much less frequently in breast
cancer (<5% of cases) than in other cancer types, such as
endometrial cancer (about 20% of cases) [15,28]. PIK3R1
mutations were observed in 2.2% of cases in the present
study. PIK3R1 mutations and p85 loss have also been as-
sociated with PI3K pathway activation and increased
oncogenic potential. However, the fact that PIK3R1 mu-
tations are rare in breast cancer indicates that PIK3R1
mRNA/p85α expression loss is the main deregulation
occurring in breast tumors, particularly in HR- breast
tumors. Another player affecting the PI3K pathway acti-
vation is PTEN, a tumor suppressor phosphatase which
negatively regulates the PI3K pathway. Loss of PTEN
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and in up to 30% of breast cancers, leading to PI3K
pathway activation [4]. Interestingly, p85 has also been
suggested to have a positive regulatory effect on PTEN
function via stabilization of this protein [15,16]. PTEN
underexpression was found in 17% cases in our series
(39% in triple-negative tumors) and was associated with
PIK3CA wild-type status and PIK3R1 underexpression,
in line with previous findings.
There is growing evidence in the literature concerning
the favorable outcome of PIK3CA-mutated breast can-
cer, as supported by the results of this study [9-12].
These mutations are known to play an activating role in
cell lines and animal models [13,14]. Several hypotheses
are currently proposed to explain the favorable prognos-
tic impact of PIK3CA mutations: 1, PIK3CA mutations,
when they are the only hit to the PI3K signaling path-
way, have a limited oncogenic potential; 2, PIK3CA muta-
tions result in oncogene-induced senescence; 3, PIK3CA
mutation-bearing cells are more sensitive to chemotherapy
and/or other treatment modalities; 4, PIK3CA mutation-
induced signaling triggers a negative feedback loop inhibit-
ing lower levels of the pathway [8,31]. PIK3CA mutations
might affect the PI3K/AKT pathway in different ways
in patient tumors and cell lines. The difference be-
tween PIK3CA mutation-related activation of the path-
way in cell lines or animal models and patient outcome
could be related to the treatment received by patients, as
suggested above. In contrast with the PIK3CA mutation-
associated survival advantage in anti-ERBB2 untreated
patients, PIK3CA mutations appear to predict resist-
ance to treatment including ERBB2 inhibitors such as
trastuzumab [32,33].
The present study demonstrates that PIK3R1 underex-
pression is associated with decreased patient survival.
Immunohistochemical analysis showed that PIK3R1
transcripts are translated into p85 protein in epithelial
tumor cells (Figure 1). A strong correlation was also
demonstrated between PIK3R1 mRNA underexpres-
sion and decreased p85 protein levels. Immunohisto-
chemistry could be the method of choice to routinely
determine p85 expression status. PIK3R1 underexpres-
sing tumors were also prone to accumulate other
changes of the PI3K/AKT pathway, i.e. PDK1 overex-
pression and EGFR, AKT3, PTEN and WEE1 underex-
pressions. PIK3R1 underexpression is therefore associated
with additional pathway deregulation and possibly also
with increased signaling activation. In a murine model
with liver-specific PIK3R1 loss, this condition led to devel-
opment of aggressive hepatocellular cancer [16]. Loss of
PIK3R1mRNA expression in cell lines was associated with
a more migratory and more invasive phenotype of MCF-
7-14 cells compared to the parental MCF-7 cell line [34].
Lu et al. described a gene expression signature includingPIK3R1 distinguishing between low- and high-risk stage I
lung cancer. The authors found low PIK3R1 expression in
high-risk compared to low-risk lung cancers [35]. Studies
concerning glioblastomas have also suggested that these
tumors might be negatively influenced by PIK3R1 expres-
sion at the level of cell lines and in terms of patient
survival [36,37]. The recently observed role of PIK3R1
expression deregulation in breast cancer survival needs
to be further assessed, preferably in a prospective clinical
study.
Our results suggest that PIK3R1 could potentially
become a clinically useful independent prognostic marker
in breast cancer. PIK3R1 underexpression (as well PIK3CA
mutation) might also predict a favorable response to
treatment with PI3K inhibitors or inhibitors of lower
levels of the signaling pathway, such as mTOR inhibi-
tors [14,28,38,39]. Finally, PIK3R1 underexpression
(and PIK3CA mutation) could be explored as predic-
tors of resistance to treatment with ERBB2 inhibitors
such as trastuzumab [12].
Conclusions
PIK3CA and PIK3R1 are genes encoding two subunits of
the PI3K enzyme, p110α and p85α, respectively. The
present study showed that alterations in these two genes
have a complementary impact on breast cancer patient
survival. There is growing evidence supporting PIK3CA
mutations as good prognostic markers in breast cancer,
but the negative impact of PIK3R1 underexpression on
patient survival has been less extensively studied. These
two potential tumor markers warrant further assess-
ment, preferably in prospective clinical studies.Additional files
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